Takeda Oncology
Ronald Gounden is an experienced professional in the field of oncology and medical affairs, currently serving as Associate Director for Disease and Product Training in Global Medical Affairs at Takeda Oncology since July 2020. Prior to this role, Ronald held various leadership positions at Takeda, including Medical Director for Singapore, Malaysia, Vietnam, the Philippines, and the Africa Cluster from December 2013 to July 2020. Ronald's earlier experience includes serving as a Senior Lecturer in Clinical Pharmacology at the University of Cape Town from July 2012 to November 2013 and as a Medical Advisor at Cipla from July 2010 to July 2012. Ronald holds a Master's degree in Clinical Pharmacology and a Bachelor's degree in Medicine, both from the University of Cape Town.
This person is not in any teams
This person is not in any offices
Takeda Oncology
20 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.